Form 4: Director Daphne Karydas Executes MLYS Stock Option Plan

Mineralys Therapeutics director Daphne Karydas exercised options and sold 3,000 shares of common stock under a 10b5-1 plan.

Summary

• Director Daphne Karydas exercised 3,000 stock options at a strike price of $12.02.
• Following the exercise, the director sold 3,000 shares of common stock at a price of $25.00 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
• The director's direct beneficial ownership of common stock stands at 6,200 shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents routine portfolio management by a director.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The director reduced their direct holdings of common stock by 3,000 shares.

Risks

• Future stock price volatility may impact the value of remaining derivative holdings.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions executed under 10b5-1 plans are standard corporate governance practices designed to provide transparency and avoid potential conflicts of interest regarding material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings in publicly traded biotechnology companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was conducted under a pre-established trading plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Insider Trading, Form 4, Stock Options, Rule 10b5-1